【邀请函】2019中欧生物医药合作暨投融资大会 Sino-Euro BioPartnering (SEBP)
规模：100人
活动时间
2019-06-14 至 2019-06-14 13:30-17:30
活动地点
上海市徐汇区枫林路420号2楼，枫林国际创新中心。2F, No. 420, Fenglin Rd, Xuhui District, Shanghai
组织单位
主办单位：枫林集团(Fenglin Group)、捷迈生物医药咨询有限公司(G-med Consulting)
承办单位：枫林国际创新中心(Fenglin Biomedical Center)、上海聚科生物园区(Shanghai JUKE Biotech Park)
指导单位：徐汇区科学技术委员会
支持单位：European Biopharmaceutical Enterprises、岸金生物科技有限公司
主题分享嘉宾：
王向东教授
王向东，医学博士，复旦大学特聘教授，复旦大学中山医院临床医学研究院执行院长，上海临床生物信息学研究所所长，上海市心肺疾病人工智能技术工程中心主任，复旦大学临床生物信息学中心主任，上海呼吸疾病研究所副所长，复旦大学中山医院研究中心主任。中国生物医药协会基因检测技术分会主任委员、中国医师协会精准医疗专业委员会副主任委员兼总干事，国际转化医学协会执行主席，中国抗癌协会肿瘤精准治疗专业委员会常委，世界华人医师协会副会长兼理事，世界华人肿瘤医师协会常务副主任委员。曾担任美国北卡罗来纳州立大学分子生物科学教授、瑞典隆德大学临床生物信息学的教授、伦敦大学国王学院兼职教授。
主要研究临床生物信息学，疾病特异性生物标志物，慢性肺疾病，肿瘤免疫学，分子和细胞疗法。开发蝶型化学结构的磷酸肌醇3-激酶抑制剂预防和治疗慢性肺部炎症和损伤。开展了精准医疗应用，融组学、生物信息学、临床信息学为一体对疾病特异性标志物识别和验证，临床跨组学，研发慢性肺疾病和肺癌的治疗靶标。正在研究肺疾病临床脂质组学与基因表达谱的相关性，用单细胞转录组研究细胞间的信号交流。
项目简介：
1.冷激光截骨手术机器人 (瑞士）:
Cool Ablation Robot Laser Osteotomy (Switzerland)
This has now been achieved by AOT AG with the ground-breaking invention of the CARLO? system (Cold Ablation Robot-guided Laser Osteotome). This system allows for the direct collaboration of man and machine by means of a small, lightweight, and custom-designed tactile robotic arm, as well as navigation and control software and its corresponding hardware. All of these elements are combined in an ergonomic system, which fits easily into the operating room and allows the surgeon full control over this universal osteotomy device at any time. CARLO? is thus the world’s first medical, tactile robot that can cut bone without contact and with cold laser technology. The device allows the surgeon to perform bone operations with unprecedented precision, and in freely-defined, curved and functional sectional configurations, which are not achievable with conventional instruments.
AOT 公司发明了世界上第一个利用冷激光消融用于截骨手术的机器人。这是一项颠覆性发明。该系统通过一个小型、轻便和灵活的机械臂以及精准的导航和软硬件控制系统直接将人和机器的协作完美结合，在手术室内能让外科医生随时掌控这种通用的截骨装置。该系统也是世界上第一款可以在不接触骨组织的前提下使用冷激光技术切割骨骼的医疗机器人。该装置允许外科医生以前所未有的精度执行骨骼操作，并且具有自由定义的，弯曲的和功能性的截面配置，这是传统仪器无法实现的。
2.治疗性肿瘤疫苗 （瑞士)
Therapeutic vaccine technology (Switzerland)
Vaxeal is a private Europe-based biotech company, incorporated in 2009;
Headquartered in Vevey in Switzerland, with subsidiaries near Paris (FR) and London (UK). Vaxeal is proposing game-changing immunotherapies in the field of cancer and is a pioneer in the development of novel combinations of CD4+/CD8+ T-cell-based immunotherapies and Immune Checkpoint Inhibitor immunotherapies.
T-cell-based immunotherapies are today at center stage of new cancer treatments (Science Magazine: “Breakthrough of the Year 2013); ASCO 2015; FDA/Novartis/Gilead 2017. VAXEAL completed pre-clinical trials of its first product, SVX-1 (combined Survivin T-cellbased LSPs/MAb anti-PD1 immunotherapy), on multiple animal and human cancer models, which shown great efficacy and no toxicity. Second candidate is already at advanced pre-clinical stage (Cyclin B1). Vaxeal expects to start clinical trials in Q3 2020. Regulatory fast track and special protocol assessment apply to each product.
私营公司Vaxeal成立于2009年，总部在瑞士沃韦，在法国巴黎和英国伦敦都设有分部。Vaxeal将带来世界领先的颠覆性联合肿瘤免疫疗法，可同时激活CD4+和CD8+两种T细胞并结合免疫检查点抑制剂。T细胞免疫疗法如今已成为肿瘤治疗的焦点。Vaxeal已对其第一款产品，SVX-1（靶向生存素的T细胞抗原表达合成长肽+PD-1单抗的联合免疫疗法）在动物和人类癌症模型上完成了临床前试验，验证了效力和无毒性。第二款针对细胞周期蛋白Cyclin B1的候选药物也已经在进行临床前试验。Vaxeal预计在2020年第三季度开始临床试验。两款产品预计都将获得监管机构快速通道和特殊评估协议。
3. NOTCH靶点肿瘤创新药 创新 临床一期 （瑞士）
NOTCH target anti-cancer new drug development (Switzerland)
Cellestia is a clinical stage biopharmaceutical company located in Basel and Lausanne, Switzerland, developing innovative first-in-class anti-cancer drugs. Our clinical stage lead compound CB-103 is an oral small molecule protein-protein interaction inhibitor, acting as selective oncogene transcription factor inhibitor providing personalized precision medicine for therapy of NOTCH positive cancers.
CB-103 combines exceptional potency, selectivity, safety and expectation of clinical efficacy based on previous NOTCH targeting agents, while overcoming the limitations of these due to its unique Mode of Action. The development is complemented by a diagnostic program for patient selection.
Cellestia是一家专注抗肿瘤一线新药的生物公司，坐落于巴塞尔和洛桑。公司的旗舰化合物CB-103口服蛋白相互作用小分子抑制剂已进入临床阶段，可对转录因子类癌基因进行选择性抑制，为NOTCH阳性的癌症提供个性化精准治疗。与前代针对NOTCH的靶向药相比，CB-103结合了出众的药力、特异性、安全性和预计临床疗效，并以独特的作用方式克服了前代靶向药的不足。该公司还有一套辅助药物研发的诊断方案以选择合适的病人。
4. 针对罕见病的基因疗法 临床前（英国）
Gene medicine company targeting rare diseases, pre-clinical (UK)
An innovative British company has developed a range of proprietary platform technologies for the delivery of RNA-targeted gene medicines. The first program is focused on addressing the spectrum of pathological changes in Duchenne muscular dystrophy. There is also a rich pipeline for blockbuster conditions. The company is looking to close a ?5 million round to take lead to the clinic and is also looking for licensees or partners to develop its pipeline.
一家位于英国的创新公司开发了一系列专有的平台技术，用于RNA靶向基因药物的精准给药。该公司的头号产品可缓解杜氏肌营养不良症的各种病理症状。该公司还有丰富的潜在特效药管线。该公司希望融资500万英镑继续开发药物并开始临床流程，也希望接触潜在的授权对象或合作研发伙伴。
5. 基于植物提取物的保健创新产品 （英国）
Unique plant-based solutions for key health benefits (UK)
A British life science company identifies active ingredients from plants with a rich history of use in traditional medicine, especially in China, and develops solutions for global health concerns. It has developed: 1. the first ever traditional Chinese medicine for joint and muscle relief approved as an OTC medicine by British authority, and 2. a proprietary plant-based product which promotes healthy blood glucose by reducing the digestion of sugar and carbohydrate by up to 40%. The company is looking for commercial partners to help distribute product 1, and formulate product 2 into food. The company also wishes to raise ?5-6 million of growth capital to conduct B2B sales and marketing around the world, formulate B2C strategies, and recruit more employees.
一家位于英国的生命科学公司从传统医学（尤其是中医）中经常用到的植物中开发活性成分，并从中为全球健康问题寻求解决方案。该公司已研发两款产品：1. 首例在英国获批的非处方中药，用于缓解肌肉和关节疼痛；2. 一种专有的植物性降糖产品，可减少40%碳水化合物的吸收。该公司正在寻找商业合作伙伴，以帮助销售产品1，并将产品2用于食品中。公司还希望融资500-600万英镑，在全球开展B2B销售，制定B2C战略，并扩充团队。
6. 针对难治性抑郁症的循证创新疗法 临床二期（英国）
Evidence-based innovative therapy for treatment-resistant depression, phase II (UK)
A British life sciences company dedicated to accelerating patient access to evidence-based innovations in mental health is currently conducting phase II trials across Europe and North America for patients with treatment-resistant depression. The company has raised ?25 million for the clinical trials and is currently embarking on a fund raise of for ?100 million for Phase III. The company welcomes China Pharma relationship and may consider licensing CFDA development.
一家位于英国的生命科学公司致力于加速为患者提供心理健康领域的循证创新疗法。目前该公司正在欧洲和北美对难治性抑郁症患者进行临床二期试验。该公司已获得2500万英镑的针对临床试验的融资，并正在为临床三期试验融资1亿英镑。该公司希望与中国药商建立联系，也可考虑中国报证程序的授权。
7.女性可穿戴生理检测(德国)
Female wearable physiology device (Germany)
Background:
1. The company is dedicated to developing wearable sensing solutions for physiological monitoring and bringing the solution to clinical trials. The company has transferred medical technology into regulatory-approved diagnostic tools, which combines sensor-based measuring device and algorithm-based intelligent assessment software to continuously search and analyze biomarkers in a telemedicine platform, in order to realize more successful and cost-effective treatment while satisfying medical needs
2. The company has developed an electronic sanitary device providing solutions for the coverage and analysis of the entire menstrual cycle for the first time. The product consists of a flexible plastic ring containing a biosensor that can stay in the vagina for as long as 30 days without being felt. The device allows for automatic measurement of body core temperature every 5 minutes and can be combined with processing software, the data can be uploaded and assessed by an algorithm which analyzes the reproductive health patterns, and the results can be visualized on a computer or mobile device.
Technology highlight:
1. The global market size for female health is expected to exceed 50 billion USD in 2025.
2. More than 70% of women of childbearing age on contraception pills have increasing demand on hormone-free contraception methods;
3. The company has a product and digital diagnostic platform which combines sensor-based wearable devices with intelligent medical algorithm-based evaluation software to detect and analyze fertility/pregnancy patterns.
4. Identifying individual reproductive health patterns and improve the success rate of fertility treatment, while reducing the number of visits, cost, and side-effects.
5. Individualized, more successful fertility and gynecological treatment reducing cost and side-effects
6. Easy-to-use, hormone-free safe contraception
7. Determine pregnancy patterns to ensure pregnancy health and prevent premature delivery
8. Ce-marked medical device and telemedicine platform enabling remote monitoring, and individualized and more effective treatment
9. Reliability of ovulation test is >99%; accuracy of fertilization is 88.8%
10. No hormones or plasticizers.
11. Suitable for across the menstrual cycle and all lifestyles.
12. Profit mode: product sales and subscription service (B2B2BC & B2C)
13. Expected revenue in 2023: EUR 86 million, 32% EBIT.
背景：
1. 一家专注从事可穿戴传感器生理监测解决方案的研究和临床试验的研发公司。公司将医疗技术转移到监管认可的诊断工具中，结合基于传感器的测量设备和基于医疗算法的智能评估软件在远程医疗平台内搜集分析用于检测连续测量的生物数据中的各个生物标记模式，满足医疗需求同时实现更成功，更具成本效益的治疗方法。
2. 其女性生理周期监控产品是一种电子卫生保健解决方案，能够首次映射和分析整个周期。该产品由一个柔性塑料环组成，该塑料环装有放置在阴道内的生物传感器。它在那里停留长达30天，女人无法感觉到。它可在整个循环中每 5分钟自动测量身体核心温度，从而可连续测量身体核心温度（BCT）。利用阅读设备和移动软件，数据被上传并评估医疗算法，检测生育模式。结果显示在计算机或移动设备的仪表板上。
技术特点：
1. 2025年全球女性健康市场估计价值超过500亿美元
2. 应用避孕药的70%+的育龄女性对对无激素方法的避孕需求不断增长
3. 标的公司推出的产品和数字诊断平台将基于传感器的可穿戴设备与基于智能医疗算法的评估软件相结合，检测和分析生育/妊娠模式。
4. 确定个体生育模式，使个体化生育治疗成功率提高，成本和副作用降低。
5. 实现个性化，更成功的生育治疗和妇科治疗，减少数量，成本和副作用。
6. 简单易用，安全避孕，不含激素。
7. 确定怀孕模式，以确保怀孕健康和预防早产。
8. CE认证的医疗设备和远程医疗平台，可实现远程患者监护和个性化，更有效的治疗。
9. 临床排卵检测的可靠性>99％，预测受精期的准确度为88.8％。
10. 产品不含激素和增塑剂。
11. 适用于所有生理周期和生活方式。
12. 盈利模式：产品销售+服务订阅 （B2B2BC & B2C）。
13. 预计2023年实现8千6百万欧元营收，32% EBIT。
8.泌尿系统疾病数字诊断治疗（西班牙）
Digital diagnosis and treatment for urinary diseases (Spain)
Background:
Established in 2012 as the world’s first digital diagnosis and treatment company for urinary diseases, the company has an innovative digital treatment platform based on urine pH management, enabling real-time tracking for pH-related urinary diseases. The company owns 9 inventions and 49 patents for diagnosis and treatment of kidney stones, and has an electronic IVD device transferring real-time data to software platforms contained in electronic devices such as mobile phones, providing patients with timely personalized information, including health warnings, metabolic assessment, urine data, dietary/lifestyle recommendations, and meanwhile offering 3 dietary supplements for urine pH adjustments. The system can allow sharing and tracking of patient data by hospitals and insurance companies, allowing for greater patient participation, improved clinical outcome, more timely treatment feedback and overall better patient experience.
Technology highlights:
1. In 2020, Chinese digital healthcare market is expected to reach $110 billion USD, while around the globe the gross market size is estimated to reach $536.6 billion USD.
2. Kidney stone has an increasing prevalence in China especially among the young and the middle-aged because of an increase in the diabetic and obese population. According to statistics, the incidence of kidney stone has increased by 70% in the past 15 years in the US. Kidney stone is usually a life-long disease which easily relapses. It is also the most expensive urological disease in the US. There are about 700 million kidney stone patients worldwide.
3. Real-time monitoring, as well as timely dietary and lifestyle interventions are very important to prevent relapses.
4. The company has a first-class digital urological treatment platform to improve clinical outcomes and reduce the costs associated with kidney medication. It also helps the diagnosis of kidney stone and other urinary tract diseases by performing tests and controlling patients’ urine pH,
5. The company has received CE marking, ISO13485, ISO9001 and has been certified by AEMPS (Spanish Agency of Medicines and Medical Devices).
6. 9 inventions, 49 patents, 6 clinical trials involving 500+ patients from 20 hospitals, with endorsements from internationally famous key opinion leaders.
7. Flexible and multi-channel recurrent revenue business model, with income from devices, dietary supplements, and subscription services.
8. Expected revenue in 2023: EUR 30 million per year, with 40% of EBITA and 15% compound annual growth rate.
背景：
标的公司成立于2012年，是泌尿系统第一个数字诊断治疗的公司。其创新的基于尿液pH值管理的数字治疗平台，可以实 时跟踪诊断PH值相关的泌尿系统疾病。针对肾结石的诊断和治疗，拥有9项发明，49项专利。已推出 IVD 电子体外诊断器械，数据通过蓝牙实时传输至手机等电子设备的软件平台，及时提供患者的个性化信息服务，包括健康警告，新陈代谢评估，尿液数据，饮食/生活方式推荐，同时提供尿液PH值调节管理的三种医疗食品。系统可与医院/保险公司等实现患者数 据信息共享和跟踪，实现更高的患者参与度，更加的治疗效果，更及时的医疗反馈和更好的患者体验。
技术特点：
1. 2020中国数字医疗市场预计达到1100亿美元，全球数字医疗市场规模将达5366亿美元。
2. 肾结石在中国的发病率逐年升高，患者以青壮年为主。由于糖尿病、肥胖人群不断增加，肾结石的发病率不断提高。据统计美国在过去15年里患病率增加70%，易复发，通常是一种终生性疾病。在美国肾结石是泌尿外科最昂贵的疾病。全球7亿肾结石病患。
3. 实时监控，并且及时调整饮食方式和生活方式对预防复发非常重要。
4. 标的公司的解决方案是泌尿外科的一流数字治疗平台，以改善临床结果并降低与肾脏药物治疗相关的成本，通过自主测试、管理尿液的pH 值诊断肾结石和其他泌尿系统疾病。
5. CE认证，ISO13485, ISO9001, AEMPS 认证。
6. 9项发明，49项专利 ，20家医院500+患者的6个临床，国际知名意见领袖的站台背书。
7. 灵活多样经常性营收商业模式：器材+医疗食品+服务订阅。
8. 2023年预计实现3千万欧元年营收，40%EBITA,15%年复合增长率。
9．磁性血液净化技术设备研发公司（瑞士）
Magnetic blood purification equipment R&D company (Switzerland)
Background:
The company has an award-winning patent for an innovative blood purification technology which provides a new approach to specific blood purification in intensive care units. Blood is pumped through an extracorporeal circuit, and nanoscale magnetic adsorbents are added. The adsorbents combine with the target substance in the blood through specific binding sites and are then removed by magnetic force. The purified blood is then transported back to the patient's body.
Technology highlights:
1. Compared with traditional blood purification methods, the company's patented technology can remove large targets, selectively adsorb disease-related compounds including bacteria, endotoxins, cytokines, and break the inflammatory cascade. Purified blood can be completely recovered through adsorbents.
2. Blood coagulation utilizes magnetic nanoadsorbents that can be covalently equipped with a specific binding agent to capture the target compound.
3. The physical limits of conventional blood purification methods in terms of target size, selectivity, and mass transfer can be overcome by engineering nanoscale adsorbent materials.
4. The core of the system is made of iron carbide, whose magnetization is 2-3 times higher than iron oxide nanoparticles and is used for most magnetic separations on laboratory scales.
5. High magnetization can be used to recover the nanoadsorbents completely and rapidly at the relevant flow rate for blood purification. This is critical for therapeutic applications in the extracorporeal blood loop, where the highest separation efficiency minimizes the potential risk of internal nanoadsurbents exposure to patients.
6. The company has global licenses for patents including magnetic core manufacturing and functionalization in the field of blood purification.
7. The solution stabilizes septic shock, shortens the hospital stay in the ICU, improves survival rate and greatly reduces medical costs.
背景：
一家致力于创新的专利获奖血液净化技术研发公司，专利血液净化技术为重症监护病房的特定血液净化提供了一种全新的方法。将血液泵送通过体外回路并添加纳米级磁性吸附剂。它们通过特异性结合位点与靶物质结合，通过磁力回收后净化的血液再输送回病患身体里。
技术特点：
1. 与传统血液净化手段相比，标的公司的专利技术可以去除大目标，有选择性去除疾病相关化合物 包括细菌，内毒素，细胞因子，打破炎症级联，纯化的血液可以完全吸附剂回收。
2. 血液凝固利用磁性纳米吸附剂，其可以共价配备特异性结合剂以捕获目标化合物。
3. 通过工程纳米级吸附剂材料可以克服常规血液净化方法在目标大小，选择性和质量传递方面的物理限。
4. 系统核心由碳化铁制成，与氧化铁纳米粒子相比，它的磁性强度高出2-3倍，用于实验室规模的大多数磁性分离。
5. 高磁化强度可以在相关的流速下快速，完整地回收纳米吸附剂，用于血液净化。这对于体外血液回路中 的治疗应用至关重要，其中最高的分离效率使内部纳米吸附剂暴露于患者的潜在风险最小化。
6. 拥有包括血液净化领域磁芯制造和功能化的等专利的全球许可。
7. 解决方案稳定感染性休克，缩短ICU的住院时间，提高存活率同时极大的降低医疗成本。
10．智能可穿戴医疗设备研发公司
Intelligent wearable medical device R&D company
Background:
A leading wearable physiological monitoring company committed to actively promoting the commercialization of healthcare. Inspired by first-class products in the consumer sector, the company provides solutions that combine medical-grade quality and reliability with ease of use and design. Its digital health solutions enable users to maintain a healthy lifestyle and improve healthcare outcomes, with the goal of reducing the cost of medical expenses. Its wearable solutions have received numerous international awards and high-quality recognition, and the management team is known worldwide for its expertise in wearable monitoring.
Technology highlights:
1. The global wearable market is expected to reach $18.9 billion in 2020, while AI+ medicine market is expected to reach $36 billion in 2025.
2. The company has 15 patents in the key fields of multi-sensor and physiological monitoring of body fatigue.
3. The product provides management and application of daily physiological health monitoring, postoperative real-time monitoring, occupational health monitoring, and other aspects.
4. The profit model is product hardware sales + ecosystem usage subscription/sharing + third-party data usage/analysis.
5. The open platform can incorporate the health analysis data of the third party.
6. Monitored indicators: heart rate, blood oxygen, skin temperature, perfusion index, respiratory rate, heart rate variability, heartbeat interval, exercise pace, stress, sleep, blood pulse, energy expenditure, sweat, health score, skin moisture, glucose trend.
背景：
一家领先的可穿戴生理监测公司。积极推动医疗保健的消费化，提供将医疗级质量和可靠性与易用性和设计相结合的解决方案，其灵感来自消费者领域的一流产品。他的数字健康解决方案支持用户保持健康的生活方式，改善医疗保健治疗效果，旨在减少医疗费用的成本负担。其可穿戴解决方案已获得多项国际奖项和高质量认可，管理团队因其在可穿戴监控方面的专业知识而享誉全球。
技术特点：
1. 全球可穿戴市场预计2020年达到189亿美元的规模，全球医疗人工智能2025年预计为360亿美元。
2. 标的公司在多传感器，身体磨损生理监测的关键领域拥有15个专利系列。
3. 产品提供了日常生理健康监测，术后实时监控，职业健康监测等方面的管理和应用。
4. 盈利模式为产品硬件销售+生态系统使用订阅/分享+第三方数据使用/分析。
5. 开放式平台可以引进第三方机构的健康分析数据。
6. 监测指标：心率，血氧，皮肤温度，血流灌注指数，呼吸频率，心率变异性，心跳间隔，运动步伐，压力，睡眠，血脉冲波， 能量消耗，流汗，健康评分，皮肤水分，葡萄糖趋势。
11．手部卫生系统和扫描仪
Hand hygiene system and scanner
Background:
An award-winning life science and medical device company has created a patented hand hygiene system and scanner as a unique automation solution that provides objective and continuous hand hygiene monitoring.
Technology highlights:
1. The hand hygiene system consists of a scanner, electronic monitoring equipment, and a cloud-based monitoring/reporting system for immediate assessment of hand rubbing technique. It uses software-based objective feedback to match personalized RFID card-based user identification.
2. It is compatible with most hospital information systems (ensuring data privacy) and has a fully customizable reporting system.
3. The hand hygiene system will save time, effort and money for hospital training staff. Employee hand hygiene is an effective way to prevent hospital-acquired infections (HAI).
4. Rapidly improve the quality and compliance of hand hygiene for clinical staff and hospital staff.
5. Track hand hygiene quality in real time for ease of management.
6. The hand hygiene system is currently sold in 20 countries in North America, Europe, and Asia. Reference materials from leading academic health centers and WHO-affiliated hand hygiene experts are available upon request. The system is supported by more than 20 peer-reviewed articles and publications.
7. The scanner and the adjacent cloud-based reporting system can be rented monthly or purchased directly as a complete system.
背景：
一家屡获殊荣的生命科学和医疗设备公司。我们创造了专利技术的手部卫生系统和扫描仪，作为一种独特的自动化解决方案，提供客观和持续的手部卫生监测。
技术特点：
1. 其手部卫生系统由扫描仪，电子监控设备和基于云的监测/报告系统组成，可立即评估手部摩擦技术。它使用基于软件的客观反馈，与个性化的基于RFID卡的用户识别相匹配。
2. 它与大多数医院信息系统兼容（确保数据隐私），并具有完全可定制的报告系统。
3. 手部卫生系统将为医院培训员工节省时间，精力和金钱。员工手部卫生是预防医院获得性感染（HAI）的 有效方法。
4. 迅速提高临床工作人员和医院工作人员的手部卫生质量和合规性。
5. 实时跟踪手部卫生质量以便管理。
6. 其手部卫生系统目前在北美，欧洲和亚洲的20个国家销售。可根据要求提供领先的学术保健中心和世卫组织附属手部卫生专家的参考资料。它得到了20多篇同行评审文章和出版物的支持。
7. 扫描仪和相邻的基于云的报告系统可作为月租，或者可以购买完整的系统。
12．脑神经调节治疗系统研发制造公司
Neuromodulation therapy system R&D Company
Background:
The company has developed a product which provides focal nerves stimulation for the six branches of the occipital and trigeminal nerves to reach the brainstem. It simultaneously affects the higher centers of the brain, which are involved in controlling and regulating pain and mood. The release of anti-nociceptive neurotransmitters, such as norepinephrine and serotonin, inhibits pain and improves mood. It can be used to treat diseases such as migraine, depression, ADHD, and insomnia.
Technology highlights:
1. The product is the world's first and only adaptive multi-channel neuromodulation system.
2. Lightweight, easy to carry, convenient for home use; low cost of treatment; real-time monitoring; artificial intelligence data analysis; simplified treatment process and reduced treatment costs.
3. The product is connected to an artificial intelligence algorithm based on big data on the cloud, in order to provide data collection, analysis and adjustment for customized treatment.
4. According to clinical data at Yale University School of Medicine, Hartford Healthcare Headache Center, Dartmouth–Hitchcock Medical Center and other flagship hospitals, 76% of patients had significantly reduced pain after using this product for 1 hour, while only 31.6% of patients reported pain reduction under traditional therapy for chronic and sporadic migraine.
5. 90% of patients with depression achieved a rapid and significant reduction in depression scores within 6 weeks of treatment at home.
6. Electronic, flexible payment methods.
背景：
通过为枕骨和三叉神经的六个分支提供局灶性神经刺激到达脑干，同时影响大脑中较高的中枢，这些中心参与控制和调节疼痛和情绪。释放抗伤害性神经递质，如去甲肾上腺素和5-羟色胺，可抑制疼痛，改善情绪。用于治疗偏头痛，抑郁，多动症，失眠等疾病。
技术特点：
1. 产品为全球第一个并且唯一的自适应多通道神经调节系统产品。
2. 轻巧，便于携带，方便在家使用；治疗费用低；随时监控；人工智能数据分析；简化治疗的过程和降低治疗费用。
3. 产品连接云端大数据人工智能算法，进行数据收集，分析，调整提供定制化治疗。
4. 经过美国耶鲁大学医学院，哈特福德医疗保健头痛中心，Dartmouth–Hitchcock医疗中心等权威医院 临床使用，证明76%的病人在使用1小时后疼痛明显减少，传统用于治疗慢性和偶发性偏头痛的方法只有31.6%的病人有疼痛减少的反馈。
5. 90%的抑郁症患者在家治疗的6周内抑郁症分数实现了快速并明显的降低。
6. 电子化，灵活的付费方式。
13．制药技术研发公司
Pharmaceutical technology R&D company
Background:
An innovative pharmaceutical development company has a proprietary technology to improve the properties of pharmaceutical products. The company can produce new crystalline and particulate forms for existing compounds, significantly improving clinical efficacy. The company has technology platforms for both small and large molecules, which can optimize processes for a variety of drug dosage forms (e.g. oral, inhalation, nasal, subcutaneous injection or sublingual administration).
Technology highlights:
1. Solutions for particle formation, formulation and process engineering catered to the global pharmaceutical and health supplement industry;
2. Ongoing development for proprietary products targeting unmet clinical needs, including female health, urinary and respiratory diseases;
3. Crystallization and particulate engineering technology based on supercritical fluid;
4. Process improvement to increase clinical efficacy, e.g. crystal polymorphic form control, insoluble drug, inhaled drug, stabilization of large molecules.
5. Resolving challenges associated with drug development (partnership with 13 of global top 20 companies)
6. Proprietary technology to develop own pipeline
7. A highly-efficient, stable and scalable pharmaceutical production process for proprietary drug delivery approved by the regulatory body. The platform is expected to create unique opportunities for improving clinical efficacy and improving the quality of life of patients.
背景:
是一家制药技术的创新技术公司，该公司使用专有技术，改善药物性能。可以结晶出药物的新晶型, 制备新型的药物微粒，从而极大地提高其临床疗效。同时拥有适用于小分子和大分子的技术支持平台，可优化一系列药物剂型（例如，口服、吸入、鼻腔，皮下注射，舌下含服给药等）
技术特点：
1. 服务于全球制药与保健行业，解决药物微粒的形成、制剂和生产工艺中的难题。
2. 开发自主创新产品，定位于未满足的临床需求和一些重要领域，包括女性健康、泌尿疾病和呼吸系统疾病等。
3. 基于超临界流体的结晶和微粒工程技术。
4. 提高药物的治疗效果，例如晶型控制、难溶药、吸入 给药、大分子药物稳定性。
5. 解决药物产品开发的挑战（与全球20强企业中的13家有合作）。
6. 利用专有技术优势开发自主立项产品。
7. 专有的给药技术是一种高效、稳定，完全可放大的药物生产工艺，并得到了药监部门的认可。其技术平台可为改善药物临床给药性能创造独特机会，以提高广大患者的生活质量。
活动已结束
